Sprycel dasatinib regulatory update

The U.K.'s NICE issued an updated preliminary appraisal recommending against the use of Sprycel dasatinib from Bristol-Myers and Tasigna nilotinib from Novartis to treat chronic myelogenous leukemia (CML) in patients intolerant to Glivec imatinib. The updated appraisal covers only 1 of 2 subgroups originally included in a November appraisal. The other subgroup - patients who are resistant to Glivec - will be incorporated into NICE's review of its current guidance for high-dose Glivec to treat CML (see BioCentury, Nov. 23, 2009). ...